Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years

Table 2 Baseline clinical characteristics of the patients of intrahepatic bile duct adenocarcinoma and sarcomatoid cholangiocarcinoma n (%)

		Adenocarcinoma	Sarcomatoid	P value
Gender	Male	155 (71.8)	9 (81.8)	0.732
	Female	61 (28.2)	2 (18.2)
Age	< 60	73 (33.8)	5 (45.5)	0.518
	≥ 60	143(66.2)	6 (54.5)
Abdominal pain	No	106 (49.1)	1 (9.1)	0.011
	Pain	110 (50.9)	10 (90.9)
Fever	No	195 (90.3)	7 (63.6)	0.022
	Fever	21 (9.7)	4 (36.4)
Jaundice	No	199 (92.1)	11 (100.0)	1.000
	Jaundice	17 (7.9)	0 (0.0)
Weight loss	No	201 (93.1)	10 (90.9)	0.561
	Weight loss	15 (6.9)	1 (9.1)
GB stone	No	164 (75.9)	8 (72.7)	0.730
	GB stone	52 (24.1)	3 (27.3)
Hepatitis	No	190 (88.0)	7 (63.6)	0.063
	CHB	21 (9.7)	3 (27.3)
	CHC	5 (2.3)	1 (9.1)
LC	No	183 (84.7)	6 (54.5)	0.022
	LC	33 (15.3)	5 (45.5)
Serum CEA	< 5 ng/mL	123 (56.9)	10 (90.9)	0.029
	≥ 5 ng/mL	93 (43.1)	1 (9.1)
Serum CA19-9	< 37 U/mL	64 (29.6)	6 (54.5)	0.098
	≥ 37 U/mL	152 (70.4)	5 (45.5)
Main mass	Single	145 (67.1)	6 (54.5)	0.513
	Multiple	71 (32.9)	5 (45.5)
Mass size	< 5 cm	90 (41.7)	1 (9.1)	0.054
	≥ 5 cm	126 (58.3)	10 (90.9)
LN metastasis	No	84 (38.9)	1 (9.1)	0.057
	LN meta.	132 (61.1)	10 (90.9)
Distant metastasis	No	140 (64.8)	4 (36.4)	0.104
	Distant meta.	76 (35.2)	7 (63.6)
TNM stage	I or II	76 (35.2)	0 (0.0)	0.018
	III or IV	140 (64.8)	11 (100.0)

CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; LC: Liver cirrhosis; LN: Lymph node.